Prof. Jean-François Baurain, medical oncologist at Cliniques universitaires Saint-Luc, Brussels and Prof. Bart Neyns, medical oncologist at VUB/UZ Brussels discuss highlights from the oral abstract session on melanoma/skin cancer.
They start with the 2-year results from the RELATIVITY-047 study, evaluating nivolumab plus relatlimab in previously untreated metastatic or unresectable melanoma. They also share their view on the final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study with pembrolizumab as adjuvant therapy in stage IIB or IIC melanoma, as well as on the distant metastasis-free survival results from the phase 2 mRNA-4157-P201/KEYNOTE-942 trial.
With the educational support of:
